Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Calidi Biotherapeutics Inc
CLDI
AMEX
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.7680
-0.002
-0.26%
Dern. MÀJ: Oct 21, 3:46 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
Calidi Biotherapeutics Financials
Calidi Biotherapeutics (CLDI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.
Benzinga Newsdesk
PRO
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share
Benzinga Newsdesk
PRO
Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share
Benzinga Newsdesk
Nasdaq Down 1%; Lowe's Posts Upbeat Earnings
Avi Kapoor
Dow Surges 100 Points; Target Shares Fall After Q2 Results
Avi Kapoor
PRO
Calidi Biotherapeutics Q2 EPS $(1.99) Misses $(0.11) Estimate
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(0.11) by 1709.09 percent. This is a 88.12 percent increase over losses of $(16.75) per
Benzinga Newsdesk
